Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
04 2021
Historique:
received: 10 09 2019
revised: 16 11 2019
accepted: 05 12 2019
pubmed: 18 2 2020
medline: 23 11 2021
entrez: 17 2 2020
Statut: ppublish

Résumé

Although predominantly urothelial, some bladder cancer and upper tract urothelial cancer (BC/UTUC) harbor histologic variants. Small cell BC (SCBC) variants comprised ˜5% of The Cancer Genome Atlas BC cohort, with a poor prognosis. We describe genomic profiles of BC/UTUC with small cell/neuroendocrine features identified in the Foundation Medicine database from June 2012 to September 2018. Of 3368 BC/UTUC samples, 3.92% (132) harbored small cell/neuroendocrine features by immunohistochemistry. Mutations were noted in: TP53 (92%), RB1 (75%), combined TP53/RB1 (72%), and TERT promoter (68%). Of the samples, 6.5% had TMB ≥ 10 mutations/Mb. RNA expression profiling of 24 pure SCBC and 51 urothelial BC (UBC) muscle-invasive samples evaluated from a separate cohort revealed a large number of differentially expressed genes with suppression of several inflammatory pathways in SCBC compared with UBC. This largest reported SCBC dataset to date confirms enrichment of signatures in SCBC similar to small cell lung cancer and describes unique gene expression compared with UBC. These findings may explain aggressive SCBC phenotype. PATIENT SUMMARY: Small cell bladder cancer (SCBC) is an aggressive subtype that microscopically resembles aggressive small cell lung cancer (SCLC). This study confirms that SCBC shares DNA changes similar to SCLC and that SCBC expresses many genes that urothelial bladder cancer does not, possibly explaining aggressive SCBC activity.

Identifiants

pubmed: 32061548
pii: S2588-9311(19)30168-3
doi: 10.1016/j.euo.2019.12.002
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

297-300

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Jean Hoffman-Censits (J)

Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA. Electronic address: Jhoffm57@jhmi.edu.

Woonyoung Choi (W)

The James Buchanan Brady Urological Institute, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.

Sumanta Pal (S)

Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte, CA, USA.

Edouard Trabulsi (E)

Department of Urology, The Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.

William Kevin Kelly (WK)

Department of Medical Oncology, The Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.

Noah M Hahn (NM)

Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.

David McConkey (D)

Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.

Eva Comperat (E)

CeRePP, Paris, France; Sorbonne Universite, GRC n°5, AP-HP, Hopital Tenon, Paris, France.

Andres Matoso (A)

Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA.

Oliver Cussenot (O)

CeRePP, Paris, France; Sorbonne Universite, GRC n°5, AP-HP, Hopital Tenon, Paris, France.

Geraldine Cancel-Tassin (G)

CeRePP, Paris, France; Sorbonne Universite, GRC n°5, AP-HP, Hopital Tenon, Paris, France.

Megan Hoi Yan Fong (MHY)

Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.

Jeffrey Ross (J)

Foundation Medicine, Inc., Cambridge, MA, USA.

Russell Madison (R)

Foundation Medicine, Inc., Cambridge, MA, USA.

Siraj Ali (S)

Foundation Medicine, Inc., Cambridge, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH